JCO Global Oncology (Aug 2022)
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations
- Christian Caglevic,
- Christian Rolfo,
- Ignacio Gil-Bazo,
- Andrés Cardona,
- Jorge Sapunar,
- Fred R. Hirsch,
- David R. Gandara,
- Gilberto Morgan,
- Silvia Novello,
- Marina-Chiara Garassino,
- Giannis Mountzios,
- Natasha B. Leighl,
- Denisse Bretel,
- Oscar Arrieta,
- Alfredo Addeo,
- Stephen V. Liu,
- Luis Corrales,
- Vivek Subbiah,
- Francisco Aboitiz,
- Franz Villarroel-Espindola,
- Felipe Reyes-Cosmelli,
- Ricardo Morales,
- Mauricio Mahave,
- Luis Raez,
- Jorge Alatorre,
- Edgardo Santos,
- Luis Ubillos,
- Daniel S.W. Tan,
- Christoph Zielinski
Affiliations
- Christian Caglevic
- Cancer Research Department, Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile
- Christian Rolfo
- Clinical Research Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
- Ignacio Gil-Bazo
- Universidad de Navarra, Department of Oncology, Pamplona, Spain
- Andrés Cardona
- Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center—CTIC, ONCOLGroup/FICMAC, Bogota, Colombia
- Jorge Sapunar
- Cancer Research Department, Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile
- Fred R. Hirsch
- Center for Thoracic Oncology. Mount Sinai Cancer, Mount Sinai Health System, Icahn School of Medicine, Joe Lowe and Louis Price Professor of Medicine, Tisch Cancer Institute, New York, NY
- David R. Gandara
- Center for Experimental Therapeutics in Cancer, UC Davis Comprehensive Cancer Center, Translational and Clinical Research Program, University of Hawaii Cancer Center, International Society of Liquid Biopsy, Sacramento, CA
- Gilberto Morgan
- Skåne University Hospital, Department of Oncology, Lund, Sweden
- Silvia Novello
- Oncology Department, AOU San Luigi, University of Turin, Turin, Italy
- Marina-Chiara Garassino
- Thoracic Oncology Program, the University of Chicago, Chicago, IL
- Giannis Mountzios
- 4th Oncology Department and Clinical Trials Unit Henry Dunant Hospital Center, Athens, Greece
- Natasha B. Leighl
- Medical Oncology Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, IHPME, Dalla Lana School of Public Health, Toronto, Canada
- Denisse Bretel
- GECOPERU, Lima, Peru
- Oscar Arrieta
- Toracic Oncology Unit, Instituto Nacional de Cancerologia de Mexico, Mexico City, Mexico
- Alfredo Addeo
- Oncology department, University Hospital Geneva, Geneva, Switzerland
- Stephen V. Liu
- Lombardi Comprehensive Cancer Center of Georgetown University, Washington, DC
- Luis Corrales
- Centro de Investigación y Manejo del Cáncer (CIMCA), San José, Costa Rica
- Vivek Subbiah
- Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Medical Oncology Research, MD Anderson Cancer Network, Clinical Center For Targeted Therapy, Division of Pediatrics UT MD Anderson Cancer Center, Houston, TX
- Francisco Aboitiz
- Centro Interdisciplinario de Neurociencias, Facultad de Medicina, Pontificia Universidad Católica, Santiago, Chile
- Franz Villarroel-Espindola
- Cancer Research Department, Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile
- Felipe Reyes-Cosmelli
- Clinical Trials Unit, Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile
- Ricardo Morales
- Cancer Research Department, Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile
- Mauricio Mahave
- Cancer Research Department, Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, Chile
- Luis Raez
- Memorial Cancer Institute/Memorial Health Care System, MCIFAU Florida Cancer Center of Excellence, Florida International University, Miami, FL
- Jorge Alatorre
- Instituto Nacional de Enfermedades Respiratorias (INER) Clínica de Oncología Torácica, México D.F., Mexico
- Edgardo Santos
- Florida Precision Oncology/a Division of Genesis Care USA, Research Services Thoracic and Head/Neck Cancer Programs Clinical, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL
- Luis Ubillos
- Instituto Nacional del Cancer, Montevideo, Uruguay
- Daniel S.W. Tan
- Department of Medical Oncology, National Cancer Centre Singapore, Singapore
- Christoph Zielinski
- Central European Cancer Center, Wiener Privatklinik, Vienna, and Central European Cooperative Oncology Group, HQ, Vienna, Austria
- DOI
- https://doi.org/10.1200/GO.22.00123
- Journal volume & issue
-
no. 8
Abstract
On February 24, 2022, a war began within the Ukrainian borders. At least 3.0 million Ukrainian inhabitants have already fled the country. Critical infrastructure, including hospitals, has been damaged. Children with cancer were urgently transported to foreign countries, in an effort to minimize interruption of their life-saving treatments. Most adults did not have that option. War breeds cancer—delaying diagnosis, preventing treatment, and increasing risk. We project that a modest delay in care of only 4 months for five prevalent types of cancer will lead to an excess of over 3,600 cancer deaths in the subsequent years. It is critical that we establish plans to mitigate that risk as soon as possible.
